{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Complete Remission (CR)"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Partial Remission (PR)"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Hematologic Improvement in Neutrophils (HI-N)"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Progressive Disease (PD)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Response to treatment was assessed after two cycles, according to International Working Group (IWG) criteria. Cytogenetic responses were monitored in patients with abnormalities at baseline.","groups":[{"description":"Patients receive oral MS-275 on days 1, 8, 15, and 22. Patients also receive sargramostim (GM-CSF) subcutaneously once daily on days 1-42 in courses 3 and 5 and on days 1-35 in courses 1, 2, 4, and 6. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. After completion of 2 courses of study therapy, patients who achieve a complete or partial response may receive an additional 4 courses. Patients who maintain stable disease for more than 2 months after completion of 6 courses of study therapy may receive an additional 6 courses at the time of disease progression, provided they meet original eligibility criteria.\n\nentinostat: Given PO\n\nsargramostim: Given SC","id":"OG000","title":"Arm I"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Response (Complete and Partial Response) in Patients With Myeloid Disorders","type":"PRIMARY","unitOfMeasure":"Participants"}